Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Federal Trade Commission
Merck
Boehringer Ingelheim
Chubb
McKinsey
Medtronic
UBS
Johnson and Johnson
Argus Health

Generated: October 18, 2017

DrugPatentWatch Database Preview

Takeda Company Profile

« Back to Dashboard

What is the competitive landscape for TAKEDA, and when can generic versions of TAKEDA drugs launch?

TAKEDA has twenty-one approved drugs.

There are eighty-three US patents protecting TAKEDA drugs and there have been two Paragraph IV challenges on TAKEDA drugs in the past three years.

There are one thousand and sixty-eight patent family members on TAKEDA drugs in fifty-nine countries and one hundred and twenty-seven supplementary protection certificates in fifteen countries.

Summary for Applicant: Takeda

International Patents:1068
US Patents:83
Tradenames:22
Ingredients:16
NDAs:21
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Takeda Pharms Usa
OSENI
alogliptin benzoate; pioglitazone hydrochloride
TABLET;ORAL022426-003Jan 25, 2013RXYesYes► Subscribe► SubscribeYY ► Subscribe
Takeda Pharms Usa
COLCRYS
colchicine
TABLET;ORAL022352-001Jul 29, 2009RXYesYes► Subscribe► Subscribe ► Subscribe
Takeda Pharms Usa
NESINA
alogliptin benzoate
TABLET;ORAL022271-003Jan 25, 2013RXYesYes► Subscribe► Subscribe ► Subscribe
Takeda Pharms Usa
DUETACT
glimepiride; pioglitazone hydrochloride
TABLET;ORAL021925-001Jul 28, 2006ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Takeda Pharms Usa
DEXILANT
dexlansoprazole
CAPSULE, DELAYED RELEASE;ORAL022287-002Jan 30, 2009ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Takeda Pharms Usa
OMONTYS PRESERVATIVE FREE
peginesatide acetate
SOLUTION;INTRAVENOUS, SUBCUTANEOUS202799-004Mar 27, 2012DISCNNoNo► Subscribe► SubscribeYY ► Subscribe
Takeda Pharms Usa
ULORIC
febuxostat
TABLET;ORAL021856-001Feb 13, 2009RXYesNo► Subscribe► SubscribeYY ► Subscribe
Takeda Pharms Usa
DEXILANT
dexlansoprazole
CAPSULE, DELAYED RELEASE;ORAL022287-002Jan 30, 2009ABRXYesYes► Subscribe► Subscribe► Subscribe
Takeda Pharms Usa
TRINTELLIX
vortioxetine hydrobromide
TABLET;ORAL204447-002Sep 30, 2013RXYesNo► Subscribe► SubscribeY ► Subscribe
Takeda Pharms Usa
OSENI
alogliptin benzoate; pioglitazone hydrochloride
TABLET;ORAL022426-003Jan 25, 2013RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Takeda

Paragraph IV activity for TAKEDA drugs

Drugname Dosage Strength Tradename Submissiondate
alogliptin and metformin hydrochloride
Tablets12.5 mg/500 mg and 12.5 mg/1000 mg
KAZANO
1/25/2017
alogliptin
Tablets6.25 mg, 12.5 mg and 25 mg
NESINA
1/25/2017
febuxostat
Tablets40 mg and 80 mg
ULORIC
2/13/2013
colchicine
Tablets0.6 mg
COLCRYS
12/23/2011
pioglitazone hydrochloride and metformin hydrochloride
Extended-release Tablets15 mg/1000 mg and 30 mg/1000 mg
ACTOPLUS MET XR
9/23/2011
dexlansoprazole
Delayed-release Capsule30 mg
DEXILANT
11/30/2010
dexlansoprazole
Capsule60 mg
DEXILANT
8/25/2010
pioglitazone hydrochloride and glimepiride
Tablets30 mg/2 mg and 30 mg/4 mg
DUETACT
12/22/2009
ramelteon
Tablets8 mg
ROZEREM
7/22/2009
pioglitazone hydrochloride and metformin hydrochloride
Tablets15 mg/500 mg and 15 mg/850 mg
ACTOPLUS MET
3/6/2008
lansoprazole
Delayed-release Orally Disinte15 mg and 30 mg
PREVACID
12/27/2006
lansoprazole
Delayed-release Pellets/Capsul15 mg and 30 mg
PREVACID
12/5/2005

Non-Orange Book Patents for Takeda

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,251,924 Pharmaceutical composition► Subscribe
7,569,697Benzimidazole compound crystal► Subscribe
6,103,742 Pharmaceutical composition► Subscribe
9,708,280Phenyl-piperazine derivatives as serotonin reuptake inhibitors► Subscribe
9,125,9101-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT.sub.3 and 5-HT.sub.1A activity for the treatment of cognitive impairment► Subscribe
6,277,869 Pharmaceutical composition► Subscribe
7,855,175Peptides that bind to the erythropoietin receptor► Subscribe
6,172,089 Pharmaceutical composition► Subscribe
6,169,099 Pharmaceutical composition► Subscribe
8,664,2251-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of pain or residual symptoms in depression relating to sleep and cognition► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Takeda Drugs

Country Document Number Estimated Expiration
Malaysia146290► Subscribe
Israel195511► Subscribe
CroatiaP20000092► Subscribe
Tunisia2009000317► Subscribe
Austria438397► Subscribe
Norway2007007► Subscribe
New Zealand330656► Subscribe
New Zealand588407► Subscribe
Germany19616486► Subscribe
CroatiaP20080509► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Takeda Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1730131/02Switzerland► SubscribePRODUCT NAME: EMPAGLIFLOZIN UND METFORMINHYDROCHLORID; REGISTRATION NO/DATE: SWISSMEDIC 65570 12.11.2015
2014011Lithuania► SubscribePRODUCT NAME: ALOGLIPTINUM; REGISTRATION NO/DATE: EU/1/13/844 20130919
128Luxembourg► SubscribePRODUCT NAME: 8-(3-AMINOPIPERIDIN-1-YL)-7-BUT-2-INYL-3-METHYL-1-(4-METHYLCHINAZOLIN-2-YLMETHYL)-3, 7-DIHYDROPURIN-2, 6-DION, LES ENANTIOMERES ET LEURS SELS, EN PARTICULIER LA LINAGLIPTINE COMBINEE AVEC DU CHLORHYDRATE DE METFORMINE. LINAGLIPTINE
2 5006-2014Slovakia► SubscribePRODUCT NAME: ALOGLIPTIN; REGISTRATION NO/DATE: EU/1/13/844/001 - EU/1/13/844/027 20130919
2009 00045Denmark► Subscribe
1Finland► Subscribe
1084705/05Switzerland► SubscribePRODUCT NAME: ALOGLIPTIN; REGISTRATION NO/DATE: SWISSMEDIC 62955 21.11.2013
00706Netherlands► SubscribePRODUCT NAME: VILDAGLIPTINE; REGISTRATION NO/DATE: EU/1/07/414/001-017 20070926
382Luxembourg► Subscribe91382, EXPIRES: 20220424
397Luxembourg► SubscribePRODUCT NAME: VORTIOXETINE OU UN SEL D ADDITION D ACIDE DE CELUI-CI PHARMACEUTIQUEMENT ACCEPTABLE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Cipla
Covington
Citi
Colorcon
Cerilliant
Federal Trade Commission
Dow
Julphar
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot